BioMed Research International

BioMed Research International / 2014 / Article
Special Issue

Advances in Computational Genomics

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 272950 | 8 pages | https://doi.org/10.1155/2014/272950

Designing Peptide-Based HIV Vaccine for Chinese

Academic Editor: Siyuan Zheng
Received15 Apr 2014
Accepted16 Jun 2014
Published06 Jul 2014

Abstract

CD4+ T cells are central to the induction and maintenance of CD8+ T cell and antibody-producing B cell responses, and the latter are essential for the protection against disease in subjects with HIV infection. How to elicit HIV-specific CD4+ T cell responses in a given population using vaccines is one of the major areas of current HIV vaccine research. To design vaccine that targets specifically Chinese, we assembled a database that is comprised of sequences from 821 Chinese HIV isolates and 46 human leukocyte antigen (HLA) DR alleles identified in Chinese population. We then predicted 20 potential HIV epitopes using bioinformatics approaches. The combination of these 20 epitopes has a theoretical coverage of 98.1% of the population for both the prevalent HIV genotypes and also Chinese HLA-DR types. We suggest that testing this vaccine experimentally will facilitate the development of a CD4+ T cell vaccine especially catered for Chinese.

1. Introduction

Over 30 million people have died from HIV/AIDS related illnesses since HIV was discovered in the 1980s. There are currently 33 million of HIV carriers [1]. The rate of new infection is still on the rise globally. In China, HIV infection is a great concern, especially in southern part of China, for example, Yunnan, Sichuan, Guangxi, and Xinjiang Provinces, where a large number of infected people are drug users. Additionally, in the regions of Henan, Hubei Provinces where people were infected through illicit blood collection, the rate of infection reached up to 60% of blood donors [2]. Highly active antiretroviral therapy (HAART), a combination of three or more antiretroviral drugs, is routinely used to treat individuals with HIV infection [3]. It significantly extends the lifespan and improves the quality of life of people infected with HIV but cannot eradicate the virus [4]. The course of treatment is life-long and the medicines are expensive. In developing countries, available antiretroviral drugs are still limited. Therefore, a preventive HIV vaccine is especially needed.

HIV genome is comprised of nine structural (Env, Gag, and Pol) and regulatory (Tat, Rev, Nef, Vif, Vpr, and Vpu) genes. The pol gene encodes for reverse transcriptase which is error prone. This leads to high mutation rate, 15–20% divergence between the nucleic acid sequences of different HIV clades, and 7–12% variability within each clade [5]. Although the base composition of HIV genome is stable [6], host immune response further increases the HIV nucleotide diversity.

Due to the extreme sequence diversity and high mutation rate of HIV, it has been difficult to develop an efficacious HIV vaccine. A successful HIV vaccine requires inducing neutralizing antibodies and cytotoxic T cell responses, both of which can only be optimally induced and maintained in the presence of a concurrent CD4+ T helper cell response [7]. Despite many years of basic and clinical research, to date, there are only three major human HIV vaccine clinical trials completed. Set up in 1998, AIDSVAX gp120 protein vaccine is the first HIV vaccine going through Phase III trial in human and targeted to induce neutralizing antibody activity. Although antibodies to homologous virus were elicited, they failed to neutralize heterologous viruses [8]. In 2004, a Phase IIb trial with Merck’s MRKAd5, which is a trivalent vaccine including gag, pol, and nef genes in an adenovirus 5 vector, is designed for inducing cytotoxic T cell responses [9, 10]. Despite the induction of significant level of IFN gamma-producing T cells, the MRKAd5 has increased the risk of HIV acquisition in vaccine recipients and failed to reduce viral load after HIV infection [11]. Later in 2009, a Phase III trial of RV144 HIV-1 vaccine was completed in Thailand, which is a vaccine combination comprised of ALVAC (a vaccine containing genetically engineered versions of gag, env, and pol inserted in canarypox vector) and AIDSVAX (a bivalent gp120 envelope protein vaccine). These vaccines are theoretically capable of eliciting both CD8+ T cell response and neutralizing antibody response. Despite neither vaccine worked alone, in the combination, they unexpectedly lowered the HIV incidence by 31.2% in vaccine recipients; however, they did not reduce viral load [12]. These large clinical trials have opened new questions and revealed new opportunities for HIV vaccine research, including a rethinking of the need for a vaccine for CD4+ T helper cells.

In order to stimulate a CD4+ T helper cell response, antigens need to be processed and presented through MHC class II molecules. The form of antigen could be either whole protein or peptide epitopes. A previous study with a subunit vaccine comprised of 18 CD4+ T helper cell epitopes has demonstrated an efficient induction of robust helper T cell response in a Phase I clinical trial in Caucasian population [13]. Whether a similar strategy works in Chinese population requires to be tested.

To select antigenic epitopes for a vaccine, one must address several issues. One, HIV exhibits high mutation rates, and thus conserved sequences may be needed to cover a given population. Two, the human leukocyte antigen (HLA) is highly polymorphic, and it restricts the proportion of individuals who will respond to a particular antigen [14, 15]. To overcome these problems, promising T cell epitopes that bind to several HLA alleles for maximal population coverage should be selected [16], and a large variety of HIV sequences should be considered in the design of a HIV vaccine.

MHC class II is a heterodimer that is comprised of a monomorphic α and a highly polymorphic β chain. There are over 400 class II alleles identified, spreading among HLA-DM, HLA-DO, HLA-DP, HLA-DQ, and HLA-DR loci. Among them DRB1 is the most polymorphic gene, consists of 221 alleles; followed by DPB1 and DQB1 that has 84 and 39 alleles, respectively. Whereas other gene loci may have only 1 or 2 alleles [17]. Therefore, DRB1 is the best choice to optimize MHC II coverage. The frequency of HLA-DRB1 serotype differs among ethnic groups. Within DRB1 allotype, DRB111 and 13 serotypes present in 16% and 14% of black population, whereas, in Caucasoid and Chinese, DRB107 and DRB111 and DRB112 and DRB115 appear in the highest percentage [17]. The above evidences support the development of a new HIV vaccine specifically for Chinese population. Such a vaccine should have higher probability in dealing with circulating HIV serotypes in China.

To overcome these complex issues of vaccine design, bioinformatics methods may help to determine common features of vaccine antigens that have potential to deal with divergent population and HIV quasispecies. Specifically, bioinformatics-based approach is the most feasible method in screening a large set of peptide epitopes and selection of promising vaccine antigens. In this study, we extracted 821 HIV sequence and 46 Chinese DRB1 alleles from public information and compiled a database. A combination of 7 public available epitope prediction algorithms was used to screen the database and identify CD4+ T cell epitopes as HIV vaccine antigens. We selected a set of 20 epitopes, which in combination could cover more than 98% of our target population.

2. Materials and Methods

2.1. Data Collection and Methods for Epitope Prediction

In total, 821 HIV whole genome sequences of Chinese population were retrieved from HIV Database (http://www.hiv.lanl.gov/) [27], and the distribution of 46 HLA-DR alleles (Table 1) was extracted from The Allele Frequency Net Database (AFND) (http://www.allelefrequencies.net/) [28].


NumberAllelesCoverage

1DRB1*01:010.0145
2DRB1*01:020.0014
3DRB1*03:010.0514
4DRB1*03:070.0009
5DRB1*04:010.0120
6DRB1*04:020.0024
7DRB1*04:030.0238
8DRB1*04:040.0082
9DRB1*04:050.0413
10DRB1*04:060.0233
11DRB1*04:070.0041
12DRB1*04:080.0075
13DRB1*04:100.0030
14DRB1*04:170.0018
15DRB1*07:010.0677
16DRB1*08:010.0018
17DRB1*08:020.0076
18DRB1*08:030.0512
19DRB1*08:040.0029
20DRB1*08:090.001
21DRB1*08:120.0011
22DRB1*09:010.0490
23DRB1*10:010.0149
24DRB1*11:010.0669
25DRB1*11:030.0015
26DRB1*11:040.0154
27DRB1*11:060.0013
28DRB1*12:010.0518
29DRB1*12:020.1048
30DRB1*13:010.0227
31DRB1*13:020.0233
32DRB1*13:030.0029
33DRB1*13:120.0025
34DRB1*14:010.0214
35DRB1*14:020.0013
36DRB1*14:030.0091
37DRB1*14:040.0078
38DRB1*14:050.0193
39DRB1*14:070.0023
40DRB1*15:010.1139
41DRB1*15:020.0418
42DRB1*15:040.0013
43DRB1*15:050.0018
44DRB1*16:010.0029
45DRB1*16:020.0401
46DRB1*16:050.0032

Total0.9520

Seven existing methods available in Immune Epitope Database (IEDB) [29] for MHC class II binding were used to predict HIV epitopes based on binding affinity between HLA DR types and HIV epitopes. These methods included Consensus method [30], NN-align (netMHCII-2.2) [31], stabilization matrix alignment method (SMM-align) [32], Sturniolo [33], average relative binding (ARB) [34], NetMHCIIpan [35], and Combinatorial library (ComLib) [30].

2.2. Epitope Selection

All epitopes are 15 amino acids in length. To be a potential epitope, it must have a MHC binding affinity threshold of IC50 = 500 nM or below. A selected epitope was removed from the epitope pool before the next prediction. The process is repeated until all epitopes were selected. All calculations of epitope selection process were conducted in INFORSENSE Knowledge Discovery Environment (KDS) software platform [36]. The mathematical model used to calculate the predictive score for each DR allele of known coverage (as listed in Table 1) is the following equations:

In the first equation , α represents the epitope; is the percentage coverage of number DRB1 allele; is the function to indicate whether the epitope exists in the combination of HIV sequence and DR allele, existence scored 1, and absence scored 0. is the sum of number of times of the binding of HIV sequence and DR allele after being standardized to the proportion of DR allele in all DRB1 alleles. All DRB1 alleles included in the study cover 95.2% all Chinese HLA-DR alleles [28].

We selected epitopes from a combined pool of epitopes through KDS platform using 7 prediction methods from IEDB with a dataset that consisted of 821 circulating HIV genome sequences in China and 46 Chinese HLA-DRB1 alleles. The epitopes bind to MHC class I molecules that were removed first, and then the value of IC50 was considered. Next, we ranked all epitopes based on the coverage score (the higher the better coverage in HIV genome and DR-HLA alleles). After an epitope has been selected, it was removed from the database before next selection. This process was repeated until 20 epitopes were selected. The workflow diagram of this procedure was illustrated in Figure 1.

3. Results

3.1. The Coverage Distribution of HLA-DR of Chinese Population

A total of 46 HLA-DR alleles were identified from AFND (Table 1). The alleles were listed and its coverage in Chinese population was given. The table showed the coverage ranged from 0.1% (DRB108:09) to 6.77% (DRB107:01) and in a total of 95.2% of the Chinese population. The sample population comprises 1704 individuals of the Han ethnicity. This information was obtained from ten regions within the mainland, China, and two other regions, Hong Kong and Singapore, where Chinese ethnicity dominates. Among them, the DRB1-02, -05, and -06 genotypes were not detected.

3.2. The Diversity of Epitope Coverage

With a combination of 7 existing epitope prediction methods in IEDB, using database comprised of 46 different DRB1 alleles and 821 full genome sequences of HIV isolates circulating in China, we then predicted 38,460,402 potential epitopes. After duplicates were removed, 21,007,527 potential epitopes remained. We scored these epitopes based on the allele coverage and total coverage score, which was in general normally distributed. As shown in Figure 2, most epitopes displayed low coverage scores, 0.1 or lower; the highest epitope count reached approximately 3000.

3.3. HIV Epitopes Specifically for Chinese Population

By using the methods described above, we obtained 20 epitopes, which in theory covered all 46 DRB1 allelic genotypes and 821 Chinese HIV sequences (Table 2). All 20 epitopes were selected for binding to MHC class II and absence of binding to MHC class I. Table 2 listed the amino acid sequences of the 20 epitopes, their location in HIV-1 gene, their percentage of coverage in HIV-1 genome sequences from 4% to 43%, the proportion in the HLA-DR allele sequences between 52% and 100%, and the total coverage in both sequences as low as 4% and the highest at 41%. One single epitope WIILGLNKIVRMYSP covered 41% of both DRB1 and Chinese specific HIV-1 genome sequences, which is of note. This epitope had been reported before [18]. In fact, 4 other predicted epitopes (LNKIVRMYSPTSILD, GFPVRPQVPLRPMTY, VDRFYKTLRAEQASQ, and LYKYKVVKIEPLGVA) have also been published previously [2224, 26] and 4 peptide sequences (PVVSTQLLLNGSLAE, LRIIFAVLSIVNRVR, ILDLWVYHTQGYFPD, and YKRWIILGLNKIVRM) were reported in patents before [1921, 25], whereas the remaining 11 epitopes have never been reported. All 20 epitopes together provided 98.1% coverage in HIV genome and HLA-DR alleles. These predicted epitopes were found in HIV-1 gag, env, pol, and nef genes. Six of them were in gag gene, 6 in env, 2 in pol, and 6 in nef.


Amino acid sequencesProtein destination1HIV%2DR%3Total 
coverage4
Specific coverage5Reference6

WIILGLNKIVRMYSPGag 26543%89%41%40.72%Younes et al., 2003 [18]
PVVSTQLLLNGSLAEEnv 26238%74%34%27.73%August et al., 2013 [19]
VQMAVFIHNFKRKGGPol 89224%93%23%9.79%NA (IEDB)
LRIIFAVLSIVNRVREnv 70224%96%26%4.39%Sette et al., 2005 [20]
ILDLWVYHTQGYFPDNef 12712%63%10% 5.37%Sette et al., 2002 [21]
LNKIVRMYSPTSILDGag 28425%100%25%1.81%Korber et al., 2001 [22]
WGIKQLQARVLAVEREnv 58822%87%20%1.25%NA
GAFDLSFFLKEKGGLNef 914%63%4%1.20%NA
VDRFYKTLRAEQATQGag 297T15%98%15%1.17%NA
GFPVRPQVPLRPMTYNef 859%65%6%0.84%Korber et al., 2002 [23]
TPGIRYQYNVLPQGWPol 29523%93%22%0.78%NA
VDRFYKTLRAEQASQGag 297S15%98%15%0.71%Bozzacco et al., 2012 [24]
RQLLSGIVQQQSNLLEnv 54927%83%26%0.56%NA
GLIYSKKRQEILDLWNef 1176%67%5%0.50%NA
KPCVKLTPLCVTLNCEnv 12617%89%16%0.28%NA
YKRWIILGLNKIVRMGag 27243%89%41%0.24%Sette et al., 2002 [25]
PLTFGWCFKLVPVDPNef 14411%52%11%0.21%NA
FGWCFKLVPVDPREVNef 1474%93%4%0.24%NA
CKQIIKQLQPALQTGGag 678%98%8%0.16%NA
LYKYKVVKIEPLGVAEnv 4896%100%6%0.14%Dzuris et al., 2001 [26]

Total specific coverage798.1%

The location of epitopes on HIV viral gene products and the first amino acid of the viral gene product.
2The epitope sequence presented in the proportion of 821 HIV genome sequences.
3The epitope sequence presented in the proportion of 46 DR alleles.
4The ratio of the epitope appeared in both 821 HIV genome and DR allele sequences.
5Calculated based on the coverage of the epitope in the rest of the dataset after removing the preceding epitope.
6Reference where the epitope had been published. NA: not available in published literature.
7Sum of specific coverage for all 20 epitopes.

We then applied the new method to a previously published HIV vaccine comprised of T helper epitopes and tested in clinical trial [13]. The table listed 17 epitopes, from gag, pol, env, and vpu genes. One published epitope that has a HIA binding IC50 above our threshold of 500, Env 566 IKQFINMWQEVKAMY, was not listed. For these epitopes, HIV coverage is from 2% to 43%, DR coverage is between 35% and 98%, and specific coverage is at highest of 41% and in sum of 69%.

4. Discussion

In this paper, we described a novel method for designing a peptide-based T helper cell vaccine for HIV, which is specific for Chinese HIV strains and Chinese MHC class II genotypes. The current method has several advantages. First, our methodology of epitope prediction is easily accessible to public use. In fact, it is a combination of all seven existing methods publically available in IEDB. The IEDB database comprises a series of most up-to-date and evidence based methods specifically created for the prediction of MHC restricted T cell epitopes. In contrast to other studies that only used one of the methods, we used them all for more accurate prediction of MHC class II restricted T helper epitopes.

So far, there are three major types of bioinformatics methods for the prediction of MHC class II restricted T helper cell epitopes. One is called matrix alignment algorithm, and these are SMM, ARB, and Sturniolo methods. This algorithm uses published T cell epitopes and their respective binding affinity to MHC class II, in terms of the IC50 value, to determine epitopes. The other relies on machine learning, and NN-align and NetMHCIIpan methods belong to this category. New sequences are subjected to computer simulated models to predict whether any epitopes can bind to a particular MHC II to high enough affinity. The third type combines several methods together to predict epitopes. These include Consensus method and ComLib method.

Consensus method was reported to provide highest true positive rate, followed by NN-align and ARB [37]. NetMHCIIpan performed the best among all other pan-specific methods for MHC class II with varied experimental settings [38]. NN-align performs especially well in handling large dataset among all other machine learning methods and in combination with ARB outperforms the use of NN-align alone [30].

In this study, we used all above seven methods simultaneously, scored the potential epitopes independently, and then used IC50 value as a filter to select T cell epitopes that have the broadest population coverage. Our method did not use all 8 IEDB recommended methods but integrated 7 of the IEDB methods because the 8th IEDB method is an integration of the other seven and thus not an independent measurement. The method we used could be considered as “greedy” algorithm in the bioinformatics field, which predicts the best epitope among all in a pool of potential epitopes. Thus, we believe an integrated method that uses a combination of all seven original algorithms might be the best to predict more accurately MHC class II epitopes.

Another unique feature of our study is that we designed candidate helper T cell vaccine targets specifically to the Chinese population. Most common world circulating HIV subtypes are B and C, and recombinant forms are AE and AG. In contrast, the common subtypes are B and recombinant forms are BC and AE in China [27, 39, 40]. We extracted all 821 subtypes of HIV-1 strains which are mostly subtypes B and C for developing a highly specific vaccine for Chinese population. As T helper cell epitopes are recognized through MHC class II, and that Chinese exhibit divergence DRB1 alleles, we also included 46 published Chinese HLA-DRB1 genotypes into our prediction.

In comparison to a previous paper that selected MHC class II binders according to the binding affinity to multiple HLA-DR subtypes [13], we focused on DRB1 alleles which are most polymorphic among human MHC class II loci and thus directed our study to be more specific and increased possibility to induce T cell responses specifically for Chinese.

One limitation in our study, as shown in Table 1, is that DRB1 genotypes 2, 5, and 6 were not included. This is due to a lack of publication of any information on DRB102, 05, and 06. Therefore, our dataset represents what is currently available; that is, there are only 46 DRB1 alleles in Chinese population.

By using our method, we obtained 20 helper T cell epitopes which covered 98.1% of HIV strains known to have been circulating in China and all Chinese HLA-DR genotypes. There are limited studies that have tested designed peptide T helper vaccine in humans. In a published paper that contains 18 T helper epitopes [13], our combination of epitope predication methods found that these epitopes covered 69% of Chinese HIV genomes (Table 3). In a different population that is predominantly Caucasian, these epitopes combined have a 100% coverage. Thus, the difference in the coverage may suggest our predicting method is more specific for Chinese population, and our epitopes are better potential HIV vaccine candidate for Chinese. Furthermore, 9 epitopes we obtained have been published before and 11 are not. Thus, we both have the empirical evidence to support that our allelic specific peptides have the potential to stimulate T cell responses and new epitopes to suggest that our prediction is innovative.


Amino acid sequenceProtein destination1HIV%2DR%3Specific coverage4

FRKYTAFTIPSINNEPol 30314%98%13%
EKVYLAWVPAHKGIGPol 7113%98%3%
GEIYKRWIILGLNKIGag 29420%87%18%
KRWIILGLNKIVRMYGag 29843%89%41%
GAVVIQDNSDIKVVPPol 98921%57%12%
YRKILRQRKIDRLIDVpu 312%89%2%
QKQITKIQNFRVYYRPol 95619%98%19%
SPAIFQSSMTKILEPPol 33511%93%11%
QHLLQLTVWGIKQLQEnv 72923%83%21%
AETFYVDGAANRETKPol 6197%41%2%
QGQMVHQAISPRTLNGag 1713%85%3%
WAGIKQEFGIPYNPQPol 8743%35%1%
KVYLAWVPAHKGIGGPol 7123%93%2%
KTAVQMAVFIHNFKRPol 91524%83%22%
EVNIVTDSQYALGIIPol 67424%57%16%
WEFVNTPPLVKLWYQPol 59622%91%22%
HSNWRAMASDFNLPPPol 75811%57%7%

Total specific coverage569%

The epitopes were selected from a published paper.
Data in columns 2–5 were calculated using the same method as in Table 2.

There was one core epitope WIILGLNKIVRMY, appeared in both studies, showing very high HIV, HLA-DR, and specific coverage. The Gag epitope with two amino acids modification WIILGLNKIVRMYSP was reported to stimulate strong CD4+ T responses [27]; another variant of the same epitope KRWIILGLNKIVRMY exhibited superior HLA-DR binding capacity [13]. Another difference between our study and that published is that our epitopes consisted of those in nef gene but not vpu gene, whereas Walker’s study did not cover nef but vpu. These comparisons suggest that a vaccine designed predominantly for Caucasian may not be optimal for Chinese population. One epitope, for instance, Env 566 (IKQFINMWQEVKAMY) [13], given in Walker’s paper, was not picked up in our study.

Our method predicted epitopes, in theory, together covered 98.1% of HIV-1 genome and Chinese specific DRB1 alleles. In comparison, Walker’s study reported 18 T helper cell epitopes that cover 100% of the global population. By using a prediction algorithm which based mostly on HLA supertypes [13]. However, when submitted to our new prediction method, the same epitopes only achieved 69% of coverage of the Chinese population. The discrepancy in methods for prediction may give different results. Further experimental evidence is required to find out whether our method is more accurate.

The allele coverage of DRB1 for Chinese was based on 1704 subjects of whom 1569 were from mainland China and 135 were from Hong Kong and Singapore. All Chinese allele data regarding DRB1 frequencies were extracted from AFND, and all 1704 subjects were Chinese Han ethnics. There is no information on other minor national groups in China available. This may lead to inaccuracy in prediction of helper T cell epitopes for the Chinese. Larger sample size may improve the quality of our prediction.

5. Conclusions

In this study, we report a novel bioinformatics method for designing peptide epitope based T helper vaccine for HIV. We suggest further in vitro and in vivo experiments to be performed to test the immunogenicity of this vaccine and improvement of method of prediction to be made when necessary.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Jiayi Shu and Xiaojuan Fan contributed equally to this work.

Acknowledgment

This work is supported by the Grant of National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Twelfth Five-Year Plan Period (2013ZX10001002002002).

References

  1. Joint, “Global report fact sheet: The global AIDS epidemic,” Edited by HIV/AIDS UNPo, 2010, http://www.unaids.org/documents/20101123_FS_Global_em_en.pdf. View at: Google Scholar
  2. Y. X. Yan, Y. Q. Gao, X. Sun et al., “Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients,” Epidemiology and Infection, vol. 139, no. 3, pp. 354–360, 2011. View at: Publisher Site | Google Scholar
  3. D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz, “Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection,” Nature, vol. 373, no. 6510, pp. 123–126, 1995. View at: Publisher Site | Google Scholar
  4. F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998. View at: Publisher Site | Google Scholar
  5. A. S. de Groot, B. Jesdale, W. Martin et al., “Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach,” Vaccine, vol. 21, pp. 27–30, 2003. View at: Publisher Site | Google Scholar
  6. A. C. van der Kuyl and B. Berkhout, “The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus,” Retrovirology, vol. 9, article 92, 2012. View at: Publisher Site | Google Scholar
  7. B. D. Walker and D. R. Burton, “Toward an AIDS vaccine,” Science, vol. 320, no. 5877, pp. 760–764, 2008. View at: Publisher Site | Google Scholar
  8. N. M. Flynn, D. N. Forthal, C. D. Harro et al., “Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection,” Journal of Infectious Diseases, vol. 191, no. 5, pp. 654–665, 2005. View at: Publisher Site | Google Scholar
  9. S. P. Buchbinder, D. V. Mehrotra, A. Duerr et al., “Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial,” The Lancet, vol. 372, no. 9653, pp. 1881–1893, 2008. View at: Publisher Site | Google Scholar
  10. M. J. McElrath, S. C. de Rosa, Z. Moodie et al., “HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis,” The Lancet, vol. 372, no. 9653, pp. 1894–1905, 2008. View at: Publisher Site | Google Scholar
  11. A. S. Fauci, M. I. Johnston, C. W. Dieffenbach et al., “HIV vaccine research: the way forward,” Science, vol. 321, no. 5888, pp. 530–532, 2008. View at: Publisher Site | Google Scholar
  12. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al., “Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand,” The New England Journal of Medicine, vol. 361, no. 23, pp. 2209–2220, 2009. View at: Publisher Site | Google Scholar
  13. L. E. Walker, L. Vang, X. Shen et al., “Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes,” Vaccine, vol. 27, no. 50, pp. 7087–7095, 2009. View at: Publisher Site | Google Scholar
  14. V. Brusic and J. T. August, “The changing field of vaccine development in the genomics era,” Pharmacogenomics, vol. 5, no. 6, pp. 597–600, 2004. View at: Publisher Site | Google Scholar
  15. I. G. Ovsyannikova, R. M. Jacobson, and G. A. Poland, “Variation in vaccine response in normal populations,” Pharmacogenomics, vol. 5, no. 4, pp. 417–427, 2004. View at: Publisher Site | Google Scholar
  16. N. C. Toussaint and O. Kohlbacher, “OptiTope—a web server for the selection of an optimal set of peptides for epitope-based vaccines,” Nucleic Acids Research, vol. 37, no. 2, pp. W617–W622, 2009. View at: Publisher Site | Google Scholar
  17. S. G. E. Marsh, P. Parham, and L. D. Barber, “No. Part 11. HLA-DR,” in The HLA Facts Book, vol. 1st, pp. 330–390, Academic Press, San Diego, Calif, USA, 2000. View at: Google Scholar
  18. S. Younes, B. Yassine-Diab, A. R. Dumont et al., “HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity,” The Journal of Experimental Medicine, vol. 198, no. 12, pp. 1909–1922, 2003. View at: Publisher Site | Google Scholar
  19. J. T. August, G. G. Simon, T. W. Tan, A. M. Khan, and Y. Hu, “Human immunodeficientcy virus (HIV-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications,” United States Patent Application US2013/0195904 A1, National University of Singapore, The Johns Hopkins University, edited by Office USP, 2013. View at: Google Scholar
  20. A. Sette, J. Sidney, S. Southwood et al., Inducint Cellular Immune Responses to Human Immunodeficiency Virus-1 Using Peptide and Uncleic Acid Compositions, vol. 20050271676, Epimmune Inc, San Diego, Calif, USA, 2005, Edited by Office USP.
  21. A. Sette, J. Sidney, and S. Southwood, HLA Class I and II Binding Peptides and Their Uses, vol. WO2003040165A2, Epimmune Inc., New York, NY, USA, 2002.
  22. B. T. M. Korber, R. Koup, B. D. Walker et al., HIV Molecular Immunology, vol. LA-UR 02, Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2001, edited by J. A. Bradac.
  23. B. T. M. Korber, R. Koup, B. D. Walker et al., “HIV molecular immunology,” in Theoretical Biology and Biophysics, J. A. Bradac, Ed., 2002. View at: Google Scholar
  24. L. Bozzacco, H. Q. Yu, J. Dengjel et al., “Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV Gag p24 protein,” PLoS ONE, vol. 7, no. 7, Article ID e41897, 2012. View at: Publisher Site | Google Scholar
  25. A. Sette, J. Sidney, and S. Southwood, “Identification of broadly reactive DR restricted epitopes,” Tech. Rep. WO 1999061916 A1, Epimmune, San Diego, Calif, USA, 2002. View at: Google Scholar
  26. J. L. Dzuris, J. Sidney, H. Horton et al., “Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules,” Journal of Virology, vol. 75, no. 22, pp. 10958–10968, 2001. View at: Publisher Site | Google Scholar
  27. C. Kuiken, B. Korber, and R. W. Shafer, “HIV sequence databases,” AIDS Reviews, vol. 5, no. 1, pp. 52–61, 2003. View at: Google Scholar
  28. F. F. Gonzalez-Galarza, S. Christmas, D. Middleton, and A. R. Jones, “Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations,” Nucleic Acids Research, vol. 39, no. 1, pp. D913–D919, 2011. View at: Publisher Site | Google Scholar
  29. R. Vita, L. Zarebski, J. A. Greenbaum et al., “The immune epitope database 2.0,” Nucleic Acids Research, vol. 38, pp. D854–D862, 2010. View at: Google Scholar
  30. P. Wang, J. Sidney, Y. Kim et al., “Peptide binding predictions for HLA DR, DP and DQ molecules,” BMC Bioinformatics, vol. 11, article 568, 2010. View at: Publisher Site | Google Scholar
  31. M. Nielsen and O. Lund, “NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction,” BMC Bioinformatics, vol. 10, article 296, 2009. View at: Publisher Site | Google Scholar
  32. M. Nielsen, C. Lundegaard, and O. Lund, “Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method,” BMC Bioinformatics, vol. 8, article 238, 2007. View at: Publisher Site | Google Scholar
  33. T. Sturniolo, E. Bono, J. Ding et al., “Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices,” Nature Biotechnology, vol. 17, no. 6, pp. 555–561, 1999. View at: Publisher Site | Google Scholar
  34. H. H. Bui, J. Sidney, B. Peters et al., “Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications,” Immunogenetics, vol. 57, no. 5, pp. 304–314, 2005. View at: Publisher Site | Google Scholar
  35. M. Nielsen, C. Lundegaard, T. Blicher et al., “Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan,” PLoS Computational Biology, vol. 4, no. 7, Article ID e1000107, 2008. View at: Publisher Site | Google Scholar
  36. Q. Lu, P. Hao, V. Curcin et al., “KDE bioscience: platform for bioinformatics analysis workflows,” Journal of Biomedical Informatics, vol. 39, no. 4, pp. 440–450, 2006. View at: Publisher Site | Google Scholar
  37. P. Wang, J. Sidney, C. Dow, B. Mothé, A. Sette, and B. Peters, “A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach,” PLoS Computational Biology, vol. 4, no. 4, Article ID e1000048, 2008. View at: Publisher Site | Google Scholar
  38. L. M. Zhang, K. Udaka, H. Mamitsuka, and S. F. Zhu, “Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools,” Briefings in Bioinformatics, vol. 13, no. 3, pp. 350–364, 2011. View at: Publisher Site | Google Scholar
  39. X. L. Yu, L. Yuan, Y. Huang et al., “Susceptibility of HIV-1 subtypes B′, CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors,” PLoS ONE, vol. 6, no. 3, Article ID e17605, 2011. View at: Publisher Site | Google Scholar
  40. W. Wang, S. Jiang, S. Li et al., “Identification of subtype B, multiple circulating recombinant forms and unique recombinants of HIV type 1 in an MSM cohort in China,” AIDS Research and Human Retroviruses, vol. 24, no. 10, pp. 1245–1254, 2008. View at: Publisher Site | Google Scholar

Copyright © 2014 Jiayi Shu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1106 Views | 446 Downloads | 5 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.